Ainos (AIMD, Financial) reported a substantial increase in Q1 revenue for 2025, rising to $106,207 compared to $20,729 in the previous year. This 412% growth was largely fueled by sales of its AI Nose products for elderly care, developed in collaboration with Nisshinbo Micro Devices. The company's innovative scent digitization technology is advancing its position in the healthcare sector.
AIMD is also expanding the use of its AI Nose technology beyond healthcare into robotics and industrial markets. Strategic partnerships have been established, including one with a prominent Japanese service robot developer and another with the leading semiconductor packaging and testing provider, to integrate AI Nose into their systems. As AI use broadens across industries, the demand for electronic nose technology is expected to soar, with the market projected to rise from $29.8 billion in 2025 to $76.5 billion by 2032.
Additionally, AIMD is aligning its healthcare applications with the projected growth of the AI healthcare market, which is anticipated to exceed $180 billion by 2030. The company's scent-based technology is poised to enhance early disease detection, providing an edge in the expanding sector. Meanwhile, industrial robot installations increased by 10% to 4.28 million units in 2024, creating promising opportunities for AI Nose in automation.
